Journal ArticleDOI
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide
Roger Stupp,Pierre Yves Dietrich,Sandrine Ostermann Kraljevic,Alessia Pica,Ivan Maillard,Phillipe Maeder,Reto Meuli,Robert C. Janzer,Gianpaolo Pizzolato,Raymond Miralbell,F. Porchet,Luca Regli,Nicolas de Tribolet,René O. Mirimanoff,Serge Leyvraz +14 more
TLDR
This regimen of concomitant chemoradiotherapy followed by adjuvant chemotherapy may prolong the survival of patients with glioblastoma.Abstract:
PURPOSE: Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM). This phase II study was performed to determine the safety, tolerability, and efficacy of concomitant radiation plus temozolomide therapy followed by adjuvant temozolomide therapy in patients with newly diagnosed GBM. PATIENTS AND METHODS: Sixty-four patients were enrolled onto this open-label, phase II trial. Temozolomide (75 mg/m2/d × 7 d/wk for 6 weeks) was administered orally concomitant with fractionated radiotherapy (60 Gy total dose: 2 Gy × 5 d/wk for 6 weeks) followed by temozolomide monotherapy (200 mg/m2/d × 5 days, every 28 days for six cycles). The primary end points were safety and tolerability, and the secondary end point was overall survival. RESULTS: Concomitant radiation plus temozolomide therapy was safe and well tolerated. Nonhematologic toxicities were rare and mild to moderate in severity. During t...read more
Citations
More filters
Journal ArticleDOI
Phase II Study of Extended-Dose Temozolomide in Patients With Melanoma
Petra Rietschel,Jedd D. Wolchok,Susan E. Krown,Scott R. Gerst,Achim A. Jungbluth,Klaus J. Busam,Katherine Smith,Irene Orlow,Katherine S. Panageas,Paul B. Chapman +9 more
TL;DR: Extended-dose TMZ therapy did not result in a 30% responses rate, and response did not correlate with MGMT expression or promoter methylation as a continuous variable, suggesting that other resistance mechanisms are important.
Journal ArticleDOI
Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation.
TL;DR: The results of pharmacokinetics study showed Temozolomide-liposomes prolonged the in vivo circulation time and increased AUC, which implied that temozolmide- Liposomes improved the therapeutic effect in the brain and reduced the toxicity in lung and heart.
Journal ArticleDOI
Status quo--standard-of-care medical and radiation therapy for glioblastoma.
Kevin P. Becker,James B. Yu +1 more
TL;DR: This review will focus on the development of temozolomide and its use along with radiation therapy as the current standard treatment for glioblastoma.
Journal ArticleDOI
The prolyl isomerase Pin1 regulates the NF-kappaB signaling pathway and interleukin-8 expression in glioblastoma.
George P. Atkinson,Susan Nozell,D K Harrison,Mark S. Stonecypher,Dung Tsa Chen,Etty N. Benveniste +5 more
TL;DR: It is demonstrated that Pin1 levels are enhanced in primary GBM tissues compared with controls, and that this difference in Pin1 expression affects the migratory capacity of GBM-derived cells, and support the notion of using Pin1 as a therapeutic target in the future.
Journal ArticleDOI
Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
Amarnath Jena,Sangeeta Taneja,Aashish Gambhir,Anil K. Mishra,Maria Mathew Dʼsouza,Sapna Verma,Puja Panwar Hazari,Pradeep Negi,Ganesh Krishna Rao Jhadav,Shanti Kumar Sogani +9 more
TL;DR: FET uptake with Cho/Cr ratio and normalized rCBVmean could be most useful to distinguish primary glioma recurrence from radiation necrosis, and maximum area under the curve is achieved with the combination of TBRmean, CBV, and Cho/ Cr values.
References
More filters
Journal ArticleDOI
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial
Walker,Eben Alexander,William E. Hunt,MacCarty Cs,Mahaley Ms,John Mealey,Norrell Ha,Owens G,Joseph Ransohoff,Charles B. Wilson,Gehan Ea,Strike Ta +11 more
TL;DR: An analysis of prognostic factors indicates that the initial performance status, age, the use of only a surgical biopsy, parietal location, the presence of seizures, or the involvement of cranial nerves II, III, IV, and VI are all of significance.
Journal ArticleDOI
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
Walker,Sylvan B. Green,David P. Byar,Eben Alexander,Batzdorf U,Brooks Wh,William E. Hunt,MacCarty Cs,Mahaley Ms,John Mealey,Owens G,Ransohoff J nd,Robertson Jt,W. R. Shapiro,Smith Kr,Charles B. Wilson,Strike Ta +16 more
TL;DR: It is suggested that it is best to use radiotherapy in the post-surgical treatment of malignant glioma and to continue the search for an effective chemotherapeutic regimen to use in addition to radiotherapy.
Journal ArticleDOI
The new WHO classification of brain tumours.
TL;DR: The new edition of the World Health Organization (WHO) book on ‘Histological Typing of Tumours of the Central Nervous System’ reflects the progress in brain tumour classification which has been achieved since publication of the first edition in 1979.
Journal ArticleDOI
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
Henry Brem,Steven Piantadosi,Steven Piantadosi,Peter C. Burger,Michael D. Walker,Robert G. Selker,N. A. Vick,K Black,Michael B. Sisti,Steven Brem,G Mohr,P Muller,R Morawetz,S.C Schold +13 more
TL;DR: Interstitial chemotherapy delivered with polymers directly to brain tumours at the time of surgery seems to be a safe and effective treatment for recurrent malignant gliomas.
Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials
Walter J. Curran,Charles B. Scott,John Horton,James S. Nelson,Alan S. Weinstein,A. J. Fischbach,C. H. Chang,Marvin Rotman,Sucha O. Asbell,Robert E. Krisch,D. F. Nelson +10 more
TL;DR: This study of malignant glioma patients used a non-parametric statistical technique to examine the associations of both pretreatment patient and tumor characteristics and treatment-related variables with survival duration and permits examination of the interaction between prognostic variables not possible with other forms of multivariate analysis.
Related Papers (5)
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi,Annie-Claire Diserens,Thierry Gorlia,Marie-France Hamou,Nicolas de Tribolet,Nicolas de Tribolet,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Warren P. Mason,Luigi Mariani,Jacoline E C Bromberg,Peter Hau,René O. Mirimanoff,J. Gregory Cairncross,Robert C. Janzer,Roger Stupp +16 more
Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more